MY ACCOUNT | NEWSLETTER |

Reverse sneezing in dogs

Inflammatory airway disorders were present in 57% of the cases


Reverse sneezing (RS) is a frequent reason for veterinary consultation, but there is scarce clinical information. The aim of this study was to describe clinical characteristics in a cohort of 30 dogs with RS. 

Clinicians retrospectively evaluated signalment, clinical features, results of diagnostic tests, final diagnosis and evolution. Sex and neuter status were equally distributed into diagnosis categories. 

A significantly higher representation of toy (<5 kg, 50%) and small-sized dogs (5-15 kg, 27%), in comparison to medium (15-30 kg, 17%) and large-sized dogs (>30 kg, 7%), was found. 

RS was the main owner concern in many of the cases (67%). Many cases presented chronic RS (60%, >3 months), with more than one episode a week (60%). Most cases had an additional clinical respiratory sign (63%) and an unremarkable physical examination (63%). 

Inflammatory airway disorders were present in 57% of the cases, followed by anatomical-functional disorders (27%) and nasal or nasopharyngeal foreign bodies (10%). Two dogs (7%) remained as open diagnoses. Episodes of RS were persistent despite the treatment in 61% of the dogs with follow-up. 

The researchers concluded that RS should be considered a marker of potential irritation of the nasopharyngeal mucosa and should always be sufficiently investigated.

Jesús Talavera, et al. “Reverse Sneezing in Dogs: Observational Study in 30 Cases.” Vet Sci. 2022 Nov 29;9(12):665. doi: 10.3390/vetsci9120665.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

EXPRESS: Serum vitamin D metabolites do not differ between cats with chronic kidney disease and healthy cats.

Like0
Dislike0

Assessment of Pancreatic Lipase Activity Using a Quantitative and a Qualitative Assay in Dogs with Chronic Kidney Disease.

Like0
Dislike0

Effects of oregano extracts, alone or in combination with other biomolecules, on growth performances and parasitological parameters of broiler chickens challenged with Eimeria spp.: a meta-analysis.

Like0
Dislike0

New study sets out to elevate asymptomatic COVID-19 surveillance practices

Like0
Dislike0

AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top